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INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal disorders
characterized by bone marrow (BM) failure and an increased
risk of transformation into acute myeloid leukemia (AML).
Typically, MDS patients are elderly and are already anemic,
leucopenic and/or thrombocytopenic upon presentation.
Despite their myeloid origin, many MDS cases show
abnormalities in B-cells, usually related to a decrease in the
B-cell production and/or an increase in apoptosis (1,2). Such
alterations may be due to an increased production demand for
essential hematopoietic cells, such as red cells and neutrophils.
Alternatively, a blockade on B-cell maturation might occur (2).
A low level of monoclonal B-cells (,56109/L) in otherwise
healthy individuals characterizes a condition called mono-
clonal B-cell lymphocytosis (MBL). The overall reported
frequency of MBL is between 0.5% and 12% of adults,
depending on the age of the population and the sensitivity of
the flow cytometry approach used to detect the B-cell clones
(3,4). MBL ismore frequently observed among the relatives of
patients with familial chronic lymphocytic leukemia (CLL)
and in individuals exposed to toxic environments. Although
coexistence of CLL and AML or CML has been sporadically
reported, the actual frequency of MBL in association with
other hematological neoplasias remains to be established.
CASE DESCRIPTION
Here, we report a 61-year-old female patient diagnosed
with both MDS and MBL. She complained of a three-month
history of fatigue associated with sustained anemia and
thrombocytopenia detected on a routine blood test.
Splenomegaly or lymphadenomegaly were not observed.
Her hemoglobin level was 3.8 g/dL, her absolute white
blood cell (WBC) count was 7.66109/L (neutrophils 68%;
eosinophils 1%; lymphocytes 23%; monocytes 9%) and her
platelet count was 346109/L. Hyposegmented neutrophils
were observed on blood film examination. The BM aspirate
was hypercellular and showed increased blast cells (9%),
marked dysplastic abnormalities in the erythroid, granulo-
cytic and megakaryocytic lineages and no ring sideroblasts.
The BM biopsy showed mild reticulin fibrosis without the
presence of lymphoid aggregates or infiltrates. Cytogenetic
analysis was inconclusive. A diagnosis of refractory anemia
with excess blasts-1 was established according to the WHO
classification and the patient received supportive therapy
consisting of red blood cell transfusions.
Five months later, the patient’s myeloblasts had increased to
15% (BM) and an abnormal karyotype (46,XX,del(9)
(q22) [20]) was detected. Immunophenotyping of BM cells
was performed using a large panel of monoclonal antibodies
in a four-color combination to analyze precursor cells,
granulocytic, monocytic and erythroid BM compartments (5)
(Table 1). Multiparameter flow cytometry confirmed the
increased number of myeloblasts (Figure 1) with an aberrant
(CD7+, CD56+), immature (CD34+, CD117+, HLA-DR+) mye-
loid (CD13+, CD33+) phenotype. No CD34+ B-cell precursors
were detected and phenotypic abnormalities were identified
in the maturing neutrophils (e.g., aberrant CD13/CD11b
expression) and in the monocytic (e.g., CD2+, CD56+) and
erythrocytic (e.g., CD71lo) compartments (Figure 1). In addi-
tion, 8% of the marrow cells were mature T-lymphocytes and
9% were mature B-lymphocytes that presented aberrant CD25
and CD22dim expression. A detailed study was performed due
to this B-cell phenotype, which demonstrated that 88% of B-
cells weremonoclonal, surface kappa light chain restricted and
a CD5+, CD19+, CD23+ and CD25+ phenotype (Figure 2).
Further analysis of the peripheral blood (PB) demon-
strated the presence of monoclonal B-lymphocytes with a
CD19+, CD20dim, CD22dim, CD5+, CD23+, CD79bdim, CD25+,
CD43+ and CD38+ phenotype, lacking in reactivity to FMC-
7, sIgM, CD10, CD103, and CD11c. The absolute PB B-
lymphocyte count was 3.06109/L and a diagnosis of
CD5+CD23+ MBL was made.
The patient was treated for MDS with daunorubicin and
cytarabine, with no response and died six months later with
AML and the persistence of the PB monoclonal B-cell
population (26109/L).
The reported case followed the guidelines of the local
ethics committees and the Helsinki Declaration. This patient
was included in a large study on MDS (6) and informed
consent was obtained after the study was approved by the
Institutional Review Board of UNIFESP (Brazil).
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DISCUSSION
Association of MDS and B-chronic lymphoproliferative
disorders (B-CLPD) is an uncommon finding that has been
sporadically described (Table 2). We found that 31 cases had
been reported since 1974. The median age at presentation
was 72 years (range: 49-95) and the male-to-female ratio was
1.2:1. Most cases corresponded to patients with MDS and
CLL (19/31) and no significant association with specific
subtypes of MDS was observed. Florensa et al. showed a
frequency of 1% of B-CLPD in a series of 1198 MDS patients
(CLL 0.5%, lymphoplasmacytic lymphoma 0.4% and multi-
ple myeloma 0.1%) (7). At present, the general consensus is
that these associations may occur randomly (8-10). In line
with this idea, we found only one case report supporting the
existence of an ontogenic association between both dis-
orders: trisomy 8 was detected in 55% of CD13+ neutrophils
and in 13% of CD19+/CD5+ B lymphocytes in a case with
MDS and systemic vasculitis, suggesting a common stem
cell precursor had generated the two neoplastic cell
populations (11).
Low numbers of circulating monoclonal B-cells in other-
wise healthy individuals has been investigated in the last
ten years. A MBL diagnosis is confirmed by the presence of
,56109/L monoclonal B-cells associated with a normal
physical examination and negative history for lymphopro-
liferative disease, as observed in our case (12). The
progression rate to CLL has been described as approxi-
mately 1-2% of MBL cases per year (12). MBL has been
observed in a significant number of healthy individuals and
in, particular, in elderly people. Despite its frequency, the
association of MBL in patients with other hematological
neoplastic diseases (e.g., MDS) remains to be established.
Table 1 - Monoclonal antibody reagents used for the
immunophenotypic characterization of myelodysplastic
syndrome (modified from Matarraz S. et al., Leukemia
2008;22:1175-83) (5).
FITC PE PerCP-Cy5.5 APC
1. HLA-DR CD117 CD45 CD34
2. HLA-DR CD123 CD45 CD34
3. CD11b CD13 CD45 CD34
4. CD36 CD64 CD45 CD34 + CD14
5. CD15 CD16 CD45 CD34
6. CD2 CD56 CD45 CD34
7. CD65 NG2 CD45 CD34
8. CD71 Glycophorin-A CD45 CD34
9. CD61 CD33 CD45 CD34
10. CD22 CD25 CD45 CD34
11. nTdT cMPO CD45 CD34
12. cCD3 CD7 CD45 CD34
13. CD19 CD79a CD45 CD34
Figure 1 - Immunophenotypic analysis of bone marrow cell compartments: the blast cells (orange) are CD34+ and CD117+ with partial
expression of CD7; the erythroblasts (purple) present glycophorin-A and low expression of CD71; the maturing granulocytes (blue)
demonstrate an anomalous maturation pattern of CD13/CD11b expression, with increased levels of CD13 and CD11b during
intermediate maturation stages; the monocytes (green) express aberrant CD2.
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To the best of our knowledge, this is the first report
describing the association of MDS and CD5+with
CD23+MBL. Interestingly, despite the presence of a mono-
clonal B-cell population, no CD34+B-cell precursors were
identified in the patient’s BM, as usually occurs inMDS cases.
Caballero et al. reported a patient with AML associated
with CLL in which the progression of CLL disease was
observed after treatment for AML and remission was
achieved (13). In contrast, the lymphoid clone remained
stable in our case, without change after therapy during the
follow-up.
MDS develops in a multistep way. An increasing number of
accumulated genetic abnormalities lead to ineffective hemato-
poiesis. In addition, it has been noted that immune dysfunction
in MDS could also contribute to the development of cytopenia
in some groups of patients. Accumulating evidence has
demonstrated the association of MDS and autoimmune
manifestations, T-cell mediated myelosuppression and cyto-
kine-induced cytopenia (14,15). Immunosuppressive therapy in
selected MDS patients results in high rates of hematological
recovery with improved survival, especially in young patients
and in the presence of HLA-DR15 (16). In addition, auto-
immune complications arewell recognized in CLL, occurring in
10% to 25% of patients at some time during the course of the
disease. Autoimmunity in CLL predominantly targets blood
constituents, most commonly red cells. The association of MBL
and immune dysfunction is uncertain, althoughMittal et al. (17)
reported a high prevalence (20%) of CLL phenotype lympho-
cytes in 31 patients with autoimmune disorders (AIHA,
idiopathic thrombocytopenic purpura and Evans’ Syndrome),
suggesting the importance of these clones in the pathogenesis of
autoimmune blood disorders.
For the reasons stated above, the coexistence of a
monoclonal B-cell disorder with MDS deserves special
interest. This is particularly true because multiparameter
flow cytometry immunophenotyping is the method of
choice to detect MBL. Although numerous reports had
described the immunophenotypic abnormalities in MDS, it
has only recently begun to be applied during the routine
work-up for the diagnosis and prognosis of potential MDS
cases (18). Moreover, our case illustrates the importance of
well-designed flow cytometry panels, capable of analyzing
all hematopoietic cell populations because more than one
neoplastic disorder may be present in the same case. We
suggest the addition of one screening tube in the MDS
investigational panel, containing CD19, CD5, anti-k and l
Figure 2 - Immunophenotypic analysis of bone marrow B-cells: monoclonal B-lymphocytes (green) are CD19+, CD5+, CD45++ and
presents dim k light chain restriction. Residual polyclonal B-lymphocytes are illustrated in red. The same immunophenotypic B-cells
were detected in the peripheral blood.
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light chains, which could be expanded when necessary.
Widespread use of flow cytometry in the routine evaluation
of MDS patients will potentially contribute to defining the
actual frequency of the association between MBL and MDS
and it may provide new insights into the association of these
disorders.
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